MARKET

SEEL

SEEL

Seelos Therapeutics Inc
NASDAQ

Real-time Quotes | Nasdaq Last Sale

1.220
+0.020
+1.67%
After Hours: 1.220 0 0.00% 16:55 09/20 EDT
OPEN
1.210
PREV CLOSE
1.200
HIGH
1.230
LOW
1.160
VOLUME
452.93K
TURNOVER
--
52 WEEK HIGH
12.82
52 WEEK LOW
1.160
MARKET CAP
31.42M
P/E (TTM)
-0.1268
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of SEEL and other stocks commission-free!

Open a Webull account and fund it to get a free stock

Analyst Rating

Based on 2 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

EPS

SEEL News

  • Three Q4'19 Catalysts For Axovant
  • Seeking Alpha - Article.5d ago
  • The Daily Biotech Pulse: Cheery Results For Sage's Depression Drug, UniQure Offering, Axsome Aces Study Of Headache Drug
  • Benzinga.09/05 12:12
  • Seelos Therapeutics to Participate in Upcoming Investor Conference in September
  • GlobeNewswire.09/04 13:00
  • Mitsubishi Tanabe launches late-stage study in U.S. for continuous Parkinson's therapy
  • Seeking Alpha - Article.08/28 14:26

More

Industry

Pharmaceuticals
+1.04%
Pharmaceuticals & Medical Research
+0.95%

Hot Stocks

Name
Price
%Change

About SEEL

Seelos Therapeutics, Inc., formerly Apricus Biosciences, Inc., is a clinical-stage biopharmaceutical company. The Company is focused on developing technologies and therapeutics for the treatment of central nervous system, respiratory disorders. The Company is engaged in developing its lead programs SLS-002 and SLS-006. The Company is also engaged in developing several preclinical programs, which include SLS-008, SLS-007 SLS-010 and SLS-012. SLS-002 is intranasal racemic ketamine with two investigational new drug applications (INDs), for the treatment of suicidality in post-traumatic stress disorder (PTSD), and in depressive disorder. SLS-006 is engaged in advancing their product candidate into late stage trials as a monotherapy in early stage Parkinson's disease patients, and as an adjunctive therapy with reduced doses of Levodapa (L-DOPA). SLS-007 is a peptide-based approach, targeting the nonamyloid component core (NACore).
More

Webull offers Seelos Therapeutics Inc (SEEL) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.